José Iglesias, M.D., is chief medical officer at HiberCell. He has more than 30 years of experience in oncology. Prior to working with HiberCell, José was vice president and head of translational medicine at Boston Biomedical Inc., where he was responsible for the clinical development of seven early pipeline compounds in immuno-oncology, solid tumor oncology and hematologic malignancies.

Previously, José was chief medical officer at Biothera where he was responsible for the clinical development program of Imprime-PGG. Prior to that, he was the chief medical officer for Bionomics where he was responsible for the clinical development of its oncology pipeline, including antivascular agents, monoclonal antibodies and small molecule kinase inhibitors. Before that, he served as vice president, clinical development, at Celgene Corporation, where he was responsible for the Phase III development of Abraxane in pancreatic cancer, lung cancer and metastatic breast cancer.

José is author or co-author of more than 60 publications in the area of Oncology, with over 6,000 citations. He received his M.D. in oncology and cancer biology from the Universidad de Montevideo, Uruguay.